20 articles
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
New cell-based treatments including CAR-T therapy could transform outcomes for systemic sclerosis patients.
Revolutionary cell therapy achieves drug-free remission in patients with severe myasthenia gravis, an autoimmune muscle disorder.
HSCT therapy achieves drug-free remission in patients with treatment-resistant autoimmune conditions like lupus and rheumatoid arthritis.
Scientists discover tumor-associated immune cells can promote nerve growth and dramatically improve spinal cord injury recovery.
A major review outlines how targeted hematologic therapies are transforming outcomes in MGRS, a rare but serious cause of kidney injury.
Breakthrough immunotherapy approach demonstrates effectiveness in treating multiple autoimmune conditions simultaneously.
Chinese researchers test safer alternative to CAR-T therapy for lupus patients, achieving remission in 67% with minimal side effects.
Engineered immune cells offer new hope for treating kidney diseases that resist standard therapies, potentially improving long-term health outcomes.
A major review in Nature Medicine explores how CAR cell therapies may achieve deep immune 'reset' in autoimmune diseases by depleting pathogenic B cells.
New research shows how targeted interleukin-2 treatment can restore regulatory T cells and reduce muscle inflammation in autoimmune conditions.
New antigen-specific tolerance approach could treat multiple sclerosis and related diseases without broad immunosuppression.
Researchers modified red blood cells to teach the immune system tolerance, potentially ending need for harsh immunosuppressive drugs.
Cancer immunotherapy drugs may enhance the body's natural healing processes by boosting regenerative immune responses.
A 2025 meta-analysis of 11 RCTs finds Tฮฑ1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
A randomized phase 2 trial finds CM313 achieves 83% response rate vs 20% placebo in treatment-resistant immune thrombocytopenia.
A Stanford RCT finds pulsed electromagnetic field therapy significantly reduces thumb CMC osteoarthritis pain at 6 weeks, even after treatment ends.
Revolutionary cancer treatment adapted for autoimmune diseases achieves drug-free remission in lupus trials, with RA applications emerging.
A mechanistic deep-dive into cutting-edge anti-inflammaging interventions โ from senolytic pharmacology and precision cytokine targeting to partial reprogramming strategies that aim to restore youthful immune homeostasis.
Stanford researchers used modified immune proteins to enhance neurogenesis and cognitive function in aged mouse brains.
